MHRA recommends Avandia withdrawal

The U.K.'s MHRA said Avandia rosiglitazone "no longer has a place on the U.K. market" after the agency conducted a review of the diabetes drug that showed the risks outweighed its benefits. MHRA, which has yet to formally withdraw the drug, said it is waiting for the final outcome of an ongoing safety review by the European Medicines Agency (EMA). The U.K. agency did say it has the authority to withdraw the drug regardless of EMA's decision. MHRA said it considers Actos pioglitazone, a diabetes drug from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), to be a safe alternative to Avandia. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) markets Avandia. ...